Aimovig (erenumab) approved for migraine prevention in US adults
Aimovig (erenumab) is the first CGRP receptor inhibitor to be approved for migraine prevention in adults in the US. Patients will self administer Aimovig 70 mg or 140 mg once a month via the SureClick autoinjector.
Read the full report here »
|